BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15756256)

  • 1. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
    Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
    Br J Cancer; 2005 Mar; 92(5):857-66. PubMed ID: 15756256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
    Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
    Int J Gynecol Cancer; 2006; 16 Suppl 2():497. PubMed ID: 17010055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk.
    Jernström H; Chu W; Vesprini D; Tao Y; Majeed N; Deal C; Pollak M; Narod SA
    Mol Genet Metab; 2001 Feb; 72(2):144-54. PubMed ID: 11161840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer.
    Henningson M; Hietala M; Törngren T; Olsson H; Jernström H
    Fam Cancer; 2011 Jun; 10(2):173-85. PubMed ID: 21113804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women.
    Bågeman E; Ingvar C; Rose C; Jernström H
    Br J Cancer; 2007 Mar; 96(5):712-7. PubMed ID: 17311016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.
    Henningson M; Bågeman E; Sandberg T; Borg A; Olsson H; Jernström H
    Fam Cancer; 2007; 6(4):445-52. PubMed ID: 17484040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
    Henningson M; Johansson U; Borg A; Olsson H; Jernström H
    Mol Hum Reprod; 2007 Apr; 13(4):231-6. PubMed ID: 17307805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families.
    Jernström H; Sellberg G; Borg A; Olsson H
    Eur J Cancer Prev; 2006 Jun; 15(3):233-41. PubMed ID: 16679866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project.
    Cleveland RJ; Gammon MD; Edmiston SN; Teitelbaum SL; Britton JA; Terry MB; Eng SM; Neugut AI; Santella RM; Conway K
    Carcinogenesis; 2006 Apr; 27(4):758-65. PubMed ID: 16332723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer among young U.S. women in relation to oral contraceptive use.
    White E; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
    Hudelist G; Wagner T; Rosner M; Fink-Retter A; Gschwantler-Kaulich D; Czerwenka K; Kroiss R; Tea M; Pischinger K; Köstler WJ; Attems J; Mueller R; Blaukopf C; Kubista E; Hengstschläger M; Singer CF
    Endocr Relat Cancer; 2007 Dec; 14(4):1053-62. PubMed ID: 18045956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families.
    Rosendahl AH; Hietala M; Henningson M; Olsson H; Jernström H
    Breast Cancer Res Treat; 2011 Jun; 127(3):785-94. PubMed ID: 21140206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
    Patel AV; Cheng I; Canzian F; Le Marchand L; Thun MJ; Berg CD; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Cox DG; Dorronsoro M; Dossus L; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Linseisen J; Lund E; Manjer J; McCarty C; Peeters PH; Pike MC; Pollak M; Riboli E; Stram DO; Tjonneland A; Travis RC; Trichopoulos D; Tumino R; Yeager M; Ziegler RG; Feigelson HS;
    PLoS One; 2008 Jul; 3(7):e2578. PubMed ID: 18596909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
    Antoniou AC; Rookus M; Andrieu N; Brohet R; Chang-Claude J; Peock S; Cook M; Evans DG; Eeles R; ; Nogues C; Faivre L; Gesta P; ; van Leeuwen FE; Ausems MG; Osorio A; ; Caldes T; Simard J; Lubinski J; Gerdes AM; Olah E; Fürhauser C; Olsson H; Arver B; Radice P; Easton DF; Goldgar DE
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):601-10. PubMed ID: 19190154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of oral contraceptives and risk of breast cancer in young women.
    Ursin G; Ross RK; Sullivan-Halley J; Hanisch R; Henderson B; Bernstein L
    Breast Cancer Res Treat; 1998 Jul; 50(2):175-84. PubMed ID: 9822222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families.
    Pasanisi P; Bruno E; Venturelli E; Manoukian S; Barile M; Peissel B; De Giacomi C; Bonanni B; Berrino J; Berrino F
    Fam Cancer; 2011 Sep; 10(3):521-8. PubMed ID: 21455766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women.
    Fehringer G; Ozcelik H; Knight JA; Paterson AD; Boyd NF
    Breast Cancer Res Treat; 2009 Jul; 116(2):413-23. PubMed ID: 18785005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.
    Biong M; Gram IT; Brill I; Johansen F; Solvang HK; Alnaes GI; Fagerheim T; Bremnes Y; Chanock SJ; Burdett L; Yeager M; Ursin G; Kristensen VN
    BMC Med Genomics; 2010 Mar; 3():9. PubMed ID: 20302654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.